EDAP TMS S.A., a medical technology firm headquartered in Lyon, France, since its inception in 1979, innovates, manufactures, and globally distributes advanced, minimally invasive medical devices. With a primary focus on addressing urological diseases through sophisticated solutions, the company operates across Asia, France, the United States, and other international markets. Its business operations are divided into three distinct segments: 1. High Intensity Focused Ultrasound (HIFU): This segment concentrates on developing and advancing HIFU technology for the minimally invasive treatment of urological and various other clinical indications. Its product portfolio encompasses the Ablatherm, an ultrasound-guided robotic HIFU device for organ-confined prostate cancer; the Ablatherm Fusion, which features proprietary fusion software that merges MRI and ultrasound images for precise targeting; and the Focal One, a robotic HIFU device specifically designed for the focal therapy of prostate cancer. The segment also provides necessary disposables, leasing and treatment-related services, and ongoing maintenance. 2. Extracorporeal ShockWave Lithotripsy (ESWL): This division is responsible for manufacturing and marketing lithotripters utilizing ESWL technology to treat urinary tract stones. Its flagship, the Sonolith i-move, is an extracorporeal shockwave lithotripter well-suited for small to mid-sized hospitals, with accompanying sales of disposable parts and electrodes. 3. Distribution Services (DIST): This segment oversees the marketing, distribution, and servicing of various medical products from third-party manufacturers, such as lasers and micro-ultrasound systems. This segment's offerings also extend to device leasing, the sale of disposables and spare parts, and comprehensive maintenance support. The company serves a broad customer base, including hospitals, urology clinics, and research institutions, leveraging both its direct marketing, sales, and service platform, as well as a network of third-party distributors and agents.
The current price of EDAP is $4.71 USD — it has decreased by -1.67% in the past 24 hours. Watch FocalTherics stock price performance more closely on the chart.
What is FocalTherics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange FocalTherics stocks are traded under the ticker EDAP.
Is FocalTherics stock price growing?▼
EDAP stock has risen by +2.84% compared to the previous week, the month change is a +12.95% rise, over the last year FocalTherics has showed a +170.69% increase.
What is FocalTherics market cap?▼
Today FocalTherics has the market capitalization of 176.34M
What were FocalTherics earnings last quarter?▼
EDAP earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.18 USD resulting in a +5.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is FocalTherics revenue for the last year?▼
FocalTherics revenue for the last year amounts to 137.96M USD.
What is FocalTherics net income for the last year?▼
EDAP net income for the last year is -41.31M USD.
How many employees does FocalTherics have?▼
As of June 16, 2026, the company has 310 employees.
In which sector is FocalTherics located?▼
FocalTherics operates in the Health & Wellness sector.
When did FocalTherics complete a stock split?▼
FocalTherics has not had any recent stock splits.
Where is FocalTherics headquartered?▼
FocalTherics is headquartered in Vaulx-en-Velin, France.